Myositis-Specific Antibodies and Myositis-Associated Antibodies in Patients With Idiopathic Inflammatory Myopathies From the PANLAR Myositis Study Group

González-Bello, Yelitza C; García-Valladares, Ignacio; Reyes-Pérez, Itzel Viridiana; García-Cerda, Daniel; Medrano-Ramírez, Gabriel; Navarro‐Zarza, José Eduardo; Andrade-Ortega, Lilia; Maradiaga-Ceceña, Marco A.; Cardenas-Anaya, Alicia; Nava-Zavala, Arnulfo Hernán; Orozco‐Barocio, Gerardo; Mercado, Mónica Vázquez-Del; Rojo-Mejía, Armando; Loyo, Esthela; Gottschalk, Paola; Iglesias-Gamarra, Antonio; Vega, Kelly Patricia; Rojas, Cilia; Mantilla, Rubén D.; Gómez, Graciela; García-Kutzbach, Abraham; Fritzler, Marvin J.; Torre, Ignacio García‐De La

doi:10.1097/rhu.0000000000001350

Cited by 10 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Idiopathic inflammatory myopathies can affect any age group, from early childhood to late adult life. The mean age of onset in our study was 47.2 years (±19.6), similar to that reported in Latin America ( 18 , 24 ) and lower than that reported in France and Greece ( 25 , 26 ). Both age over 45 years and male sex have been the demographic parameters most frequently associated with an increased risk of malignancy in patients with IIM ( 27 ).…”

Section: Discussionsupporting

confidence: 86%

“…It is important to highlight the usefulness of autoantibody associations to establish a phenotypic pattern with diagnostic, prognostic, and therapeutic implications in IIM. This study is the first study in the Southwest of Colombia to describe phenotypic characteristics of autoantibody profiles and is the second to report the frequency of myositis-associated/specific autoantibodies ( 18 ). When faced with a patient with IIM, two different perspectives could be taken.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population

et al. 2022

View full text Add to dashboard Cite

ObjectivesIdiopathic inflammatory myopathies (IIMs) are chronic, autoimmune diseases with several forms of presentation. Diagnosis is mostly clinical in our region. Our aim was to evaluate the autoantibody profile of patients with IIMs.MethodsThis study is a cross-sectional study with a prospective recollection of data, conducted between 2019–2021, in a single center in Cali, Colombia. Patients with a clinical diagnosis or suspicion of IIM were included. The presence of myositis-specific/associated antibodies was evaluated by immunoblotting in serum samples. Phenotypic characterization was performed.ResultsA total of 36 patients were included. The mean age was 50.6 (16.7) years, and 20 (55.6%) were female. Eighteen (50%) patients were seropositive, of which 11 (30.5%) presented one positive antibody, with anti-TIF1ɣbeing the most frequent (n = 4, 11.1%), followed by anti-Ro52 (n = 2, 5.6%). Seven patients (19.4%) showed >1 positive antibody. Dermatomyositis was the most frequent type of IIM in seropositive patients (n = 8, 44.4%), followed by anti-synthetase syndrome (n = 4, 22.2%). Weakness was symmetric and presented in the upper and lower extremities in 11 (61.1%) patients each. Both respiratory insufficiency and weight loss were seen in 7 (38.9%) patients, Gottron papules in six (33.3%) patients, and heliotrope rash, esophageal dysmotility, and myalgia in 5 (27.8%) patients. Pulmonary interstitial disease was seen in 4 (22.2%, with antibodies for anti-Ro52, anti-MDA5 + anti-Jo1 + anti-TIF1ɣ, anti-MDA5 + anti-SAE1 + anti-NXP2, and anti-cN1A + anti-Ro52) patients, and malignancy was seen in 2 (11.1%) patients (1 with anti-Mi2β and 1 with anti-TIF1ɣ + anti-Mi2α). In all, 7 (19.4%) patients required intensive care (2 seropositive, 1 with anti-PL7, 1 with anti-MDA5 + anti-Jo1 + anti-TIF1ɣ), and 1 (2.8%) (seronegative) patient died.ConclusionThis study is the first study in the Southwest of Colombia that evaluates myositis-specific/associated antibodies in IIM. Half of the patients were seropositive. Anti-TIF1ɣwas the most frequent MSA and anti-Ro52 was the most frequent MAA. Several patients presented antibody combinations. Further studies are needed to fully associate phenotypes with antibodies.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Our study shows the association of MSA and MAA with IIM, ILD, and CTD are much higher at the strong positive antibody level when compared with the weak positive. However, the diagnostic yield of MSA was generally lower than previously reported studies [16,17]. This may be because of a relatively short follow-up in our population compared to other published studies or may be due to testing in patients with a lower pre-test probability.…”

Section: Discussioncontrasting

confidence: 74%

Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study

et al. 2021

View full text Add to dashboard Cite

Myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) are a feature of the idiopathic inflammatory myopathies (IIM), but are also seen in other rheumatic diseases, and in individuals with no clinical symptoms. The aim of this study was to assess the clinical utility of MSA and MAA and in particular the clinical relevance of weakly positive results. We included all patients at our institution who had at least one positive result on the Immunoblot EUROLINE myositis panel over a 6-year period (2015–2020). Associations with clinical features and final diagnosis were evaluated. Eighty-seven of 225 (39%) myositis panel tests met the inclusion criteria. There were 52 strong positives and 35 weak positives for one or more MSA/MAAs. Among the strong positive group, 15% (8/52) were diagnosed with IIM, 34.6% (18/52) with interstitial lung disease, 7.7% (4/52) with anti-synthetase syndrome, 25% (13/52) with connective tissue disease, and others accounted for 25% (13/52). In weak-positive cases, only 14% (5/35) had connective tissue disease and none had IIM. 60% (21/35) of weak-positive cases were not associated with a specific rheumatic disease. A significant number of positive myositis panel results, particularly weak positives, are not associated with IIM or CTD.

show abstract

“…MSA and MAA antibody distribution was more or less comparable with other cohorts [ Table 4 ][ 15 16 17 18 19 23 24 ] with the exception of lower prevalence of Mi-2 than the older Indian, PLANLAR group and Mexican cohorts. These cohorts, however, had a higher prevalence of DM compared to other groups accounting for the higher Mi-2 ratio.…”

Section: Discussionsupporting

confidence: 55%

“…Anti Ro antibody, usually Ro52 is seen in around 25-35% of the patients. [ 15 16 17 18 19 ] It is frequently associated with ARS antibodies and when occurs together has a poorer prognosis and increased risk of relapse. [ 6 20 ] Other MAA like anti-Ku antibody and anti Pm/Scl are associated with scleroderma overlap,[ 6 21 ] while Ku antibodies also have higher incidence of ILD that is steroid resistant.…”

Section: Introductionmentioning

confidence: 99%

The Association of Myositis Specific Antibodies in Patients with Inflammatory Myositis

Negalur¹,

Ekbote²,

Raval³

et al. 2021

Annals of Indian Academy of Neurology

View full text Add to dashboard Cite

Context: Autoantibodies have a role in the diagnosis and prognosis in Autoimmune Inflammatory Myositis (AIM). Aims: The aim of this work was to study the prevalence and clinical correlation of myositis specific and associated antibodies (MSA and MAA) in AIM. Setting and Design: This was a cross-sectional observational study. Methods and Materials: Consecutive AIM patents were divided into groups as dermatomyositis (DM), polymyositis (PM), CTD-associated myositis (CTD-M), cancer-associated myositis (CAM) and juvenile myositis (JM). Their data along with serum samples were collected after obtaining informed consent. Sera was analyzed for IgG antibodies against Jo-1, PL-7, PL-12, EJ, SRP, Mi-2, MDA-5, TIF1γ, SAE1, SAE2, NXP2 and SSA/R052kD using the microELISA technique. The institutional ethics committee approved the study. Statistical Analysis: SPSS software (version 24.0) was used. P value < 0.05 was considered statistically significant. Results: There were 48 patients (DM = 19, PM = 19, CTD-M = 5, CAM = 2, JM = 3) included. MSA were positive in 37.5% patients. Antibodies against Mi-2 were present in 6 (12.5%), Jo-1 in 5 (10.4%), 2 (4.1%) each had PL-7 and SRP antibodies. One patient (2%) each had MDA-5, NXP2 and TIf1g antibodies. Jo-1 antibody was associated with mechanic's hands and ILD. There was a significant association of rash in the Mi-2 group with none of the patients having ILD. Malignancy screening was negative in NXP2 and TIF1g antibody-positive patients. Ro52 was the most common MAA (33.3%) and was associated with mechanic's hand. Conclusion: MSA was present in almost 40% of the cohort. Anti Jo-1 antibody was associated with mechanic's hands and ILD. None of the Mi-2 patients had ILD, which may point to a protective role of this antibody for ILD. The association of newer antibodies in Indian patients needs to be further studied in larger cohorts.

show abstract

Myositis-Specific Antibodies and Myositis-Associated Antibodies in Patients With Idiopathic Inflammatory Myopathies From the PANLAR Myositis Study Group

Cited by 10 publications

References 42 publications

Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population

Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population

Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study

The Association of Myositis Specific Antibodies in Patients with Inflammatory Myositis

Contact Info

Product

Resources

About